1 Khullar V, Firpi RJ.Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol,2015,7:1843-1855.
2 Mario Z, Lens S, Gambato M, et al.Advances in hepatitis C therapies. Expert Opin Pharmacother,2015,28:1-15.
3 Cheetham TC, Niu F, Chiang K, et al.Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System. J Manag Care Spec Pharm,2015,21:641-647.
4 Binder J, Tetangco S, Weinshank M,et al.Development of hepatitis C virus chimeric replicons for identifying broad spectrum NS3 protease inhibitors. Antiviral Res,2011,91:102-111.
5 Cavalcante LN, Lyra AC.Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol,2015,7:1617-1631.
6 Wada Y, Tamai H, Kawashima A, et al.Prediction of a null response to pegylated interferon α-2b plus ribavirin in patients with high viral load genotype 1b hepatitis C. Gut Liver,2014,8:421-427.
7 Audrey C, Raffaele B.Liver transplantation for hepatitis C virus in the era of direct-acting antiviral agents. Curr Opin HIV AIDS,2015, 10: 361-368
8 DiMeo N, Stinco G, Fadel M, et al. Erythema Annulare Centrifugum in the Era of Triple Therapy With Boceprevir Plus Pegylated Interferon α-2b and Ribavirin for Hepatitis C Virus Infection. J Cutan Med Surg,2015, 19:203-204.
9 王媛媛,聂青和,高禄化. BILN 2061、Telaprevir及Boceprevir治疗慢性丙型肝炎临床药效比较,传染病信息, 2012,25:117-121.
10 Cui X, Kong Y, Jia J.Efficacy and safety of simeprevir in combination with peginterferon and ribavirin for patients with hepatitis C genotype 1 infection: Ameta-analysis of randomized trials. Rev Esp Enferm Dig,2015, 107: 591-597.
11 Ende AR, Kim NH, Yeh MM, et al.Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep,2015, 9:164.
12 Bhatia HK, Singh H, Grewal N, et al.Sofosbuvir: A novel treatment option for chronic hepatitis C infection. J Pharmacol Pharmacother,2014, 5:278-284.
13 Stedman C.Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential.Therap Adv Gastroenterol,2014, 7:131-140.
14 Jacobson IM, Gordon SC, Kowdley KV,et al.Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options.N Engl Med,2013, 368:1867-1877.
15 Eric Lawitz, Fred Poordad, Diana M Brainard, et al.Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis.Hepatology,2015, 61: 769-775.
16 Fazel Y, Lam B, Golabi P, et al.Safety analysis of sofosbuvir and ledipasvir for treating hepatitis C. Expert Opin Drug Saf,2015, 14:1317-1326.
17 Naggie S, Cooper C, Saag M, et al.Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med,2015, 373: 705-713.
18 Temesgen Z, Rizza SA.Daclatasvir for the treatment of chronic hepatitis C virus infection. Drugs Today (Barc) ,2015,51:277-288.
19 Nelson, James N. Cooper, Jacob P.Lalezari, et al.All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase III Study. Hepatology,2015, 61: 1127-1135.
20 Eric Lawitz, Fred Poordad, Diana M Brainard, et al.Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology,2015, 61: 769-775.
21 Shiffman ML, James AM, Long AG, et al.Treatment of Chronic HCV With Sofosbuvir and Simeprevir in Patients With Cirrhosis and Contraindications to Interferon and/or Ribavirin. Am J Gastroenterol,2015, 110: 1179-1185.
22 Hill L.Hepatitis C Virus Direct-Acting Antiviral Drug Interactions and Use in Renal and Hepatic Impairment. Top Antivir Med,2015, 23:92-96. |
